p53 modulation of Fas/Apo-1 mediated apoptosis in a human renal cell carcinoma cell line

International Journal of Oncology

Volumn 12, Issue 2, 1998, Pages 469-473

  Miyake, Hideaki ^a   Hara, Isao ^a   Gohji, Kazuo ^a   Arakawa, Soichi ^a   Kamidono, Sadao ^a  

^a KOBE UNIVERSITY   (Japan)

Author keywords

Apoptosis; Fas Apo 1; p53; Renal cell carcinoma

Indexed keywords

PROTEIN P53;

APOPTOSIS; ARTICLE; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL;

EID: 0031907378     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.2.469     Document Type: Article

References (22)

1. Parker SL, Tong T, Bolden S and Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 65: 5-27, 1996.
2. Concolino G, Marocchi A, Conti C, Tenaglia R, Di Silverio F and Bracci U: Human renal cell carcinoma as a hormone-dependent tumor. Cancer Res 38: 4340-4344, 1978.
3. Aulitzky W, Gastl G, Aulitzky WE, Herold M, Kemmler J, Mull B, Frick J and Huber C: Successful treatment of metastatic renal-cell carcinoma with a biologically active dose of recombinant interferon-gamma. J Clin Oncol 7: 1875-1884, 1989.
4. Krigel RL, Padavic-Shaller KA, Rudolph AR, Konrad M, Bradley EC and Comis RL: Renal-cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon. J Clin Oncol 8: 460-467, 1990.
5. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bringner SH, Collins FS, Weston A, Modali R, Harris CC and Vogelstain B: Mutations in the p53 gene occur in diverse human tumor types. Nature 342: 705-708, 1989.
6. Uhlman DL, Nguyen PL, Carlos Manivel J, Aeppli D, Resnick JM, Fraley EE, Zhang G and Niehans GA: Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst 86: 1470-1475, 1994.
7. Suzuki Y, Tamura G, Satodate R and Fujioka T: Infrequent mutation of p53 gene in human renal cell carcinoma detected by polymerase chain reaction-single stranded conformation polymorphysm analysis. Jpn J Cancer Res 83: 233-235, 1992.
8. Oda H, Nakatsuru Y and Ishikawa T: Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinoma. Cancer Res 55: 658-662, 1995 .
9. Nagata S: Fas and Fas ligand: a death factor and ils receptor. Adv Immunol 57: 129-144, 1994.
10. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T and Nagata S: Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol 6: 1567-1574, 1994.
11. Egle A, Villunger A, Kos M, Bock G, Gruber J, Auer B and Greil R: Modulation of Apo-I/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2. Eur J Immunol 26: 3119-3126, 1996.
12. Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, Kiefer MC, Umansky SR, Glover RA and Cohen MB: Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 57: 1758-1768, 1997.
13. Tomita Y, Bilim V, Kawasaki T, Takeda M, Kota T, Ismail O, Magnusson K and Wiman K: Frequent expression of bcl-2 in renal-cell carcinomas carrying wild-type p53. Int J Cancer 66: 322-325, 1996.
14. Kyo E, Yokozaki H, Yanagihara K, Yasui W, Ito M, Sano T, Lee PS, Saya H and Tahara E: Reduced tumorigenecity and cell motility of a gastric carcinoma cell line by introduction of wildtype p53 gene. Int J Oncol 3: 265-271, 1993.
15. Miyake H, Hanada N, Nakamura H, Kagawa S, Fujiwara T, Hara I, Gohji K, Arakawa S, Kamidono S and Saya H: Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene (In press).
16. Miyake H, Hara I, Gohji K, Yoshimura K, Arakawa S and Kamidono S: Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line. Cancer Lett (In press).
17. Robson CG: Radical nephrectomy for renal cell carcinoma. J Urol 89: 37-42, 1963.
18. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E and Radinsky R: Wild-type p53 and a tenperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15: 3032-3040, 1995.
19. Slingerland JM, Jenkins JR and Benchimol S: The transforming and supressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. EMBO J 12: 1029-1037, 1993.
20. Watanabe-Fukunaga R, Brannan CI, Itoh N, Yonehara S, Copeland NG, Jenkins NA and Nagata S: The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 148: 1274-1279, 1992.
21. Tamura T, Aoyama N, Saya H, Haga H, Futami S, Miyamoto M, Koh T, Ariyasu T, Tachi M, Kasuga M and Takahashi R: Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells. Oncogene 11: 1939-1946, 1995.
22. Nonomura N, Miki T, Yokoyama M, Imazu T, Takada T, Takeuchi S, Kanno N, Nishimura K, Kojima Y and Okuyama A: Fas/Apo-1-mediated apoptosis of human renal cell carcinoma. Biochem Biophys Res Commun 229: 945-951, 1996.